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1. Abstract 
 
 
Objectives: Renovascular disease leads to arterial hypertension and decreases 
renal function, which both impair endothelial function, a cardiovascular surrogate 
marker. Two markers of endothelial function, flow-mediated dilatation and reactive 
hyperemia, are easily and non-invasively assessable by ultrasound. The aim of this 
study was to investigate the impact of percutaneous transluminal renal artery 
angioplasty (PTRA) with stenting on endothelial function and arterial blood pressure 
in patients with renal artery stenosis (RAS). 
Methods: Flow mediated dilatation of the brachial artery, flow velocities and shear 
stress were measured with high resolution ultrasound in 24 hypertensive patients 
with renal artery stenosis (RAS) prior and after revascularization by PTRA with 
stenting. Endothelial-independent brachial dilatation was measured after application 
of nitroglycerin. 
Results: Endothelial-dependent dilatation improved from 2.4 ± 0.9% to 6.1 ± 1.4% 
(p=0.03), whereas endothelial-independent dilatation did not change after PTRA. 
Endothelial-dependent reactive hyperemic blood flow increased from 195 ± 40ml/min 
to 536 ± 94ml/min (p=0.0008), whereas endothelial-independent hyperemia did not 
increase after revascularization. After PTRA, shear stress at rest decreased from 37 
± 11 to 23 ± 3 dyne/cm² (p<0.0001), and reactive hyperemic shear stress increased 
from 89 ± 29 to 107 ± 12 dyne/cm² (p=0.014). The impact of PTRA on arterial blood 
pressure resulted in a mean decrease of 21 ± 5mmHg in systolic pressure 
(p<0.0001), of 9 ± 2 mmHg in diastolic pressure (p=0.03), and of 14 ± 5mmHg in 
peripheral pulse pressure (p=0.00039), respectively.  
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Conclusion: Endovascular treatment of renovascular disease improves endothelial 
function and leads to a decrease in resting shear stress. Therefore, endovascular 
treatment of RAS may have a beneficial effect on cardiovascular risk. 
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2. Introduction 
 
 
Renovascular disease may cause arterial hypertension through up-regulation of the 
renin-angiotensin-aldosterone system. In addition, angiotensin II does not only cause 
vasoconstriction – one factor in renovascular disease for arterial hypertension - but 
also activates NAD(P)H oxidase, a major source of reactive oxygen species located 
in smooth muscle cells (1). Reactive oxygen species inactivate endothelial nitric 
oxide, a potent vasodilator. Therefore, renovascular disease leads to lower nitric 
oxide (NO) bioavailability and hence an impaired vasodilatatory response. 
Catheter-based percutaneous renal intervention has become a widely accepted 
therapy to treat arterial hypertension and/or renal insufficiency caused by 
renovascular disease. The effect of percutaneous transluminal renal artery 
angioplasty (PTRA) on arterial hypertension in patients with atherosclerotic 
renovascular disease is currently under debate (2-4). An important human in-vivo 
study elucidated the pathophysiology of oxidative stress and vascular function in 
renovascular disease (5). Higashi et al. demonstrated that oxidative stress decreases 
and endothelial dependent dilatation improves following successful PTRA. However, 
they used invasive vascular testing with brachial artery puncture for the application of 
vasoactive drugs and subsequent plethysmographic flow assessment to measure 
endothelial dependent dilatation (5). 
In recent years, non-invasive assessment of the endothelial function known as flow-
mediated dilatation (FMD) and reactive hyperemia, assessed by high resolution 
duplex ultrasound at the brachial artery, has become widely accepted and shown to 
be correlated with systemic NO bioavailability (1). In addition, decreased FMD has 
been shown to be seen in early phases of atherosclerosis which is helpful in 
establishing the diagnosis and prognosis of coronary heart disease (6,7,8,9). It is 
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also associated with an increased risk for cardiovascular events in patients 
undergoing peripheral arterial surgery (10). 
The goal of this study was to investigate the effect of PTRA in patients with renal 
artery stenosis (RAS) on flow-mediated dilatation and reactive hyperemia, assessed 
non-invasively by high-resolution ultrasound and on arterial blood pressure. 
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3. Methods 
 
 
Patients 
Patients with arterial hypertension and/or renal insufficiency and unilateral or bilateral 
RAS (>70%) on duplex scan and angiography were eligible. Exclusion criteria were: 
recent peripheral arterial or coronary interventions or surgery within the last three 
months, chronic inflammatory diseases and liver disease. Twenty-four patients (15 
men, mean age 70 years, range 50-84) were included. The local ethical committee 
had approved the study (EK-1293) and all patients had given written informed 
consent. 
 
Study Design 
The study was conducted at a tertiary referral centre as a prospective, open, non-
randomised, single-arm, follow-up evaluation, assessing the efficacy of PTRA in 
patients with RAS on FMD, vasodilatatory capacity and peripheral blood pressure 
(systolic, diastolic, mean and pulse pressure).  
 
Endothelial Dependent Flow-mediated Dilatation and Hyperemic Flow Reserve 
Parameters (brachial artery flow-mediated and nitrate-mediated dilatation, hyperemic 
flow reserve, mean arterial and peripheral pulse pressure) were assessed one day 
prior to and one day after PTRA. Measurements were taken after an overnight period 
of rest. Patients were asked to refrain from smoking, as well as from consuming 
caffeine and taking antihypertensive drugs for at least 24 hours. Hydration 12 hours 
prior to the assessment of brachial diameter was standardized with intravenous 
sodium chloride infusion of 1000ml/12 hours and 500ml/12 hours fluids orally. 
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Duplex ultrasound assessment of endothelial-dependent FMD of the brachial artery 
was determined in accordance with recently issued guidelines (11). The study was 
performed between 8 a.m. to 10 a.m. in a temperature-controlled room (20-22°C) 
with subjects resting in the supine position prior to and after the intervention. Brachial 
artery diameter was measured two to five cm above the cubital fossa using a high-
resolution (15-MHz line array) transducer ultrasound system (Sequoia, Siemens, 
Erlangen, Germany) equipped with electronic callipers, vascular software for two-
dimensional imaging, colour and spectral Doppler, and internal electrocardiogram. A 
sphygmomanometric cuff was placed on the forearm. Baseline diameter and Doppler 
flow signals were recorded. The cuff was inflated at least 50mmHg above the systolic 
pressure to occlude arterial flow for 5 minutes. Immediately after cuff release Doppler 
flow signals were recorded during 15 seconds. Measurements were made at the end 
of the diastole between 30 to 90 seconds after cuff release. After a rest of 10 
minutes, to allow return of the brachial artery diameter and flow to baseline state, 2-
dimensional brachial images were recorded for a period of 2 minutes and repeated 4 
minutes after sublingual application of 0.4mg nitroglycerin. 
Blood flow at baseline and during hyperemia was calculated from mean velocity and 
vessel diameter. FMD was expressed as percentage change from the baseline. 
Brachial artery shear stress was calculated as 8 x blood viscosity (Px brachial artery 
flow velocity (V) / diameter of the brachial artery. Blood viscosity was assumed to be 
0.035 dyne-sec/cm2. Off-line measurements were performed on a personal computer 
using the analysis software Brachial Reactivity Analysis (Siemens, Erlangen, 
Germany). The response of the vessel diameter to reactive hyperemia was 
calculated and expressed as a percent change relative to the diameter immediately 
before cuff inflation. 
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Systolic, Diastolic, Mean Blood Pressure and Peripheral Pulse Pressure 
Systolic and diastolic blood pressures were measured using the Riva Rocci method. 
Mean arterial blood pressure is expressed as diastolic blood pressure + 1/3 x 
(systolic pressure – diastolic pressure) and the peripheral pulse pressure as the 
systolic minus the diastolic pressure. The peripheral pulse pressure is considered to 
be a superior predictor for cardiovascular mortality compared to the systolic or 
diastolic values alone (12). Blood pressures were assessed in recumbent position 
after a rest of 10 minutes 24 hours pre- and postinterventionally between 8 a.m. and 
10 a.m. 
 
Non-invasive Renovascular Assessment 
Only patients with unilateral or bilateral stenosis of >70% were included. The 
following duplex criteria for relevant stenosis had been used: Reno-aortic peak 
systolic velocity ratio >3.5, and/or renal artery peak systolic velocity >1.8m/s, 
differences in resistance index of >0.05 (unilateral stenosis). Follow-up duplex scans 
were done in all subjects at least one day after the intervention and prior to the 
assessment of endothelial reactivity and hyperemic response, to rule out acute recoil 
or residual stenosis of the treated artery. Hemodynamic criteria for successful 
revascularization included reno-aortic peak systolic velocity ratio <1.5, renal artery 
peak systolic velocity <1.2m/s and absent differences in resistance indices (<0.05). 
 
Percutaneous Transluminal Renal Angioplasty with Stenting 
Percutaneous renal intervention was performed using a 6-F arterial introducer 
inserted in the femoral artery. Patients with renal artery stenosis were included when 
systolic and mean aorto-renal pressure gradient were greater than 30mmHg and 
15mmHg, respectively. Peak and mean renal artery pressure and after drawback of 
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the guiding catheter aortic pressures were recorded. Subsequently stent implantation 
was performed in all patients. In the case of tight stenosis the option of predilatation 
was left to the discretion of the interventionalist. Balloon expandable stents were 
implanted and postdilatation performed as needed. Final angiogram and pressure 
measurement (systolic pressure gradient <10mmHg, mean pressure gradient 
<10mmHg) were performed to confirm technical success. Post-interventional therapy 
consisted of acetylsalicylic acid 100mg/d and clopidogrel 75mg/d for 4 weeks. 
 
Statistics 
Data are expressed as mean ± standard deviation (SD). Data were analyzed using 
Wilcoxon signed rank test for intra-group comparisons. Statview 5.0.1 was used as 
statistical software. A p-value <0.05 was considered to be significant. 
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4. Results 
 
 
Patients Characteristics 
Characteristics of patients with atherosclerotic RAS at baseline are shown in Table 1. 
 
 
 
 
Table 1. Baseline Characteristics of the 24 Patients with 
Atherosclerotic Renovascular Disease 
Mean age, years (range) 70 (50-84) 
Females, % (n) 37.5 (9) 
Body-Mass Index, kg/m² ( ± SD) 27.2 (± 4.7) 
Cardiovascular risk factors, % (n)  
Hypertension 100 (24) 
Diabetes mellitus 25 (6) 
Dyslipidemia 75 (18) 
Smoking 46 (11) 
Cardiovascular Comorbidities, % (n)  
Coronary artery disease 46 (11) 
Cerebrovascular disease 13 (3) 
Peripheral arterial disease 38 (9) 
Bilateral renal artery stenosis, % (n) 28 (7) 
Cardiovascular Medication, % (n) 
Beta-blocker 
ACE-Inhibitor 
Angiotensin receptor blocker 
Calcium channel blocker 
Diuretics 
 
50 (12) 
58 (14) 
25 (6) 
58 (14) 
63 (15) 
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Effects of PTRA on Brachial Artery Diameter and Flow Characteristics 
There was no significant difference between baseline and follow-up measurements of 
brachial artery diameter at rest. Although brachial artery diameter tended to be larger 
after PTRA during hyperemia and after sublingual nitroglycerin application, these 
differences were not significant (Table 2). 
When FMD was calculated as percentage increase from resting to hyperemic 
brachial diameter, there was a significant increase between baseline (2.4 ± 0.9%) 
and postinterventional FMD (6.1 ± 1.4%, p=0.03), respectively (Figure 1a), whereas 
endothelial independent FMD did not change (10 ± 1.7 % to 14 ± 2.7 %, p=0.28). 
 
Shear Stress and Flow Volume before and after Percutaneous Renal 
Intervention 
Resting flow volume and shear stress decreased significantly after PTRA (Table 2), 
whereas mean velocity did not change. 
Similarly, the vasodilatation with nitroglycerin produced a lower flow volume and 
shear stress after PTRA compared to measurements before PTRA (p=0.01 and 
p<0.0001, respectively), whereas mean velocity tended to be lower (p=0.06). In 
contrast, hyperemia produced a significantly higher flow volume, higher mean 
velocity and higher shear stress after PTRA. In addition, when changes of hyperemic 
flow reserve were calculated as percentage increase to resting values, endothelial 
dependent hyperemic flow reserve increased by more than twofold from 195 ± 40% 
to 536 ± 94% (p=0.0008), whereas endothelial independent hyperemic flow reserve 
did not change significantly (35 ± 17% to 46 ± 24 %, p=0.85, Figure 2a and b). 
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Table 2. Brachial Ultrasound Results in Patients with Renovascular Disease  
at Baseline and after Percutaneous Renal Intervention 
 
 
 
 
Baseline 
 
after PTRA 
 
 
p 
 
Resting 
Brachial artery diameter, mm (SD) 
Flow volume, mL/min (SD) 
Mean velocity, cm/sec (SD) 
Shear stress, dyne/cm² (SD) 
 
 
 
3.95 (0.14) 
54 (7.9) 
46(10) 
37 (11) 
 
 
3.90 (0.16) 
37 (5.1) 
29 ( 3) 
23 (3) 
 
 
n.s. 
0.03 
n.s. 
<0.0001 
 
Hyperemic 
Brachial artery diameter, mm 
Flow volume, mL/min  
Mean velocity, cm/sec  
Shear stress, dyne/cm²  
 
 
 
4.05 (0.1) 
124 (17) 
111 (20) 
89 (29) 
 
 
4.13 (0.2) 
166 (20) 
139 (14) 
107 (12) 
 
 
n.s. 
0.0087 
0.017 
0.014 
 
Nitroglycerin* 
Brachial artery diameter, mm 
Flow volume, mL/min 
Mean velocity, cm/sec 
Shear stress, dyne/cm²  
 
 
4.38 (0.16) 
72 (16) 
51 (16) 
38 (15) 
 
 
4.44 (0.18) 
43 (7) 
26 (4) 
18 (3) 
 
 
n.s. 
0.01 
n.s. 
<0.0001 
 
All values are mean and standard deviation (SD) 
*n=21 for nitrogylcerin-mediated dilatation. Three patients had a contraindication 
or declined to take nitrogylcerin. 
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Figure 1. Increase in Percent Changes in Brachial Artery Diameter at Baseline and 
after PTRA. 
Data are represented in means and standard deviations. Endothelium-dependent 
dilatation (Panel A) was significantly improved following PTRA, whereas endothelium-
independent dilatation (Panel B) was non-significantly enhanced. 
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Figure 2. Increase in Percent Changes in Brachial Arterial Flow Reserve. 
Data are represented in means and standard deviations. Endothelium-dependent 
(hyperemic) flow reserve significantly rose after PTRA (Panel A), and endothelium-
independent (nitrogylcerin-mediated) flow reserve did not significantly improve. 
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Systolic and Diastolic Arterial Blood Pressure and Peripheral Pulse Pressure 
before and after Percutaneous Renal Intervention 
Systolic and diastolic arterial blood pressure were significantly reduced by 21 ± 
5mmHg (p<0.0001) and 6 ± 2mmHg (p<0.03), respectively. Mean arterial blood 
pressure dropped by 14 ± 4mmHg and the peripheral pulse pressure by 12 ± 5mmHg 
(p=0.0003). 
 
 
 
Table 3. Effects of Percutaneous Renal Intervention on Systolic and Diastolic 
Blood Pressure, Mean Arterial Pressure and Peripheral Pulse Pressure 
 
 
 
Baseline Follow-up p 
 
Systolic blood pressure, mmHg  
 
 
164 (5) 
 
143 (5) 
 
<0.0001 
 
Diastolic blood pressure, mmHg 
 
 
88 (3) 
 
79 (2) 
 
0.03 
 
Mean arterial blood pressure, mmHg 
 
 
125 (4) 
 
111 (3) 
 
0.0002 
 
Peripheral pulse pressure, mmHg  
 
 
78 (5) 
 
64 (5) 
 
0.0003 
All values are mean and standard deviation (SD). 
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5. Discussion 
 
 
Renovascular disease increases angiotensin II causing peripheral vasoconstriction 
as well as deterioration of endothelial function through oxidative stress (5,13). This 
results in impairment of vascular compliance in terms of arterial stiffness and 
endothelial dependent vasodilatation, both known to be associated with poorer 
cardiovascular prognosis (14-17). 
We assessed endothelial function utilising a non-invasive method through high-
resolution ultrasound, to evaluate the association of PTRA on endothelium-
dependent and -independent brachial artery changes. FMD was introduced in 1992 
by Celermajer et al., and has since been used by numerous groups to monitor 
endothelial function (11,18). An increase in shear stress, e.g. post-ischemic, results 
in an increase tangential force exerted by blood flow over the surface of the 
endothelium. This leads to a rapid activation of endothelial nitric oxide synthase, and 
consecutive nitric oxide formation, which results in dilatation of the vessel, usually the 
brachial artery (19-22). Since this method provides a valuable status of local vascular 
nitric oxide availability, the improvement of FMD in our study can be directly related 
to a better nitric oxide status (1). Based on previously reported data, PTRA lowers 
angiotensin II and thereby improves nitric oxide bioavailability (5). The present 
findings of improved endothelial-dependent dilatation and hyperemic blood flow 
reflect those of Higashi et. al (5). After PTRA, brachial artery diameter at rest did not 
differ from preinterventional values, but mean velocity was lower at rest following 
PTRA, resulting in a lower resting shear stress. In contrast, hyperemic flow was 
increased after PTRA, representing lower peripheral microvascular resistance and 
inducing a significantly higher shear stress and endothelium dependent 
vasodilatation. This increase after PTRA indicates an improved vascular reserve. 
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Reactive hyperemia is a fundamental response of the vasculature to facilitate rapid 
oxygen delivery to tissues after a period of ischemia. Hyperemic blood flow peaks 
within a few seconds after restoration of flow, but declines rapidly thereafter resulting 
in the aforementioned endothelial dependent dilatation, which occurs 30 to 90 
seconds after cuff release. The reactive hyperemia depends on numerous factors 
such as adenosine, prostaglandins, potassium, pH, hydrogen peroxide and 
endothelium derived nitric oxide. Several studies have investigated the impairment of 
reactive hyperemia in relation to cardiovascular events and proposed that this 
impairment is related to increased cardiovascular risk (6,7,10). This has been 
assessed in patients with coronary and peripheral arterial disease. Both, reduced 
FMD and hyperemic flow velocities were shown to be associated with increased risk 
for future cardiovascular events (6,10). Whether this is true or not for patients with 
renovascular disease remains to be determined in prospective studies. However, 
previous studies have shown that the presence of RAS in patients undergoing 
coronary angiography is a strong independent predictor of mortality (23). 
Vascular flow propagation is the combination of steady flow (mean arterial blood 
pressure) and pulsatile (pulse pressure) components. Although peripheral pulse 
pressure at the level of the brachial artery does not adequately portray the pulsatile 
load to the heart like the central pulse pressure, there is recent evidence that 
increased central pulse pressure is closely related with an increase of peripheral 
pulse pressure (24). Therefore, the reduction in peripheral pulse pressure and mean 
arterial pressure, as demonstrated, could indicate an improved vascular compliance. 
Furthermore, as there is widespread agreement that elevated pulsatile load is 
associated with increased risk of cardiovascular disease, these reductions in 
pressure parameters might not only in part be related to the brachial artery 
hemodynamic, but indicate that the micro- and macrovascular changes following 
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PTRA could result in lower cardiovascular risk. Zeller et al. demonstrated that PTRA 
induces regression of left ventricular mass that is independent of the reduction in 
blood pressure. Therefore, further evaluation using the peripheral pulse pressure as 
well as the assessment of flow-mediated dilatation could contribute to better 
understanding of these favourable physiological changes due to PTRA (25). 
As this is a non-randomized observational study of a subgroup of individuals with 
renovascular disease, our findings cannot be gerenalized to all patients with 
renovascular disease. In addition, the effect of PTRA on vascular function might also 
be achieved by optimal use of antihypertensive medication. In contrast the ASTRAL 
trial report that PTRA is not superior to conservative medical treatment alone in 
patients with renal artery stenosis regarding cardiovascular and renal endpoints. 
Future randomized studies are needed to compare the effects of best medical 
treatment and PTRA on vascular function. 
In conclusion, PTRA resulted in an improved endothelial function and reduction of 
peripheral pulse pressure suggesting amelioration of systemic vascular compliance. 
This might have implications for cardiovascular prognosis in patients with renal artery 
disease.  
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